Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
4.04 USD | +0.25% | +3.12% | +7.13% |
05-09 | NeuroBo Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
05-08 | Maxim Initiates NeuroBo Pharmaceuticals With Buy Rating, $10 Price Target | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+7.13% | 19.77M | |
+3.97% | 111B | |
+11.49% | 105B | |
-12.66% | 22.34B | |
-3.70% | 21.93B | |
-6.03% | 18.59B | |
-35.21% | 18.12B | |
-10.63% | 16.96B | |
+2.85% | 13.7B | |
+36.82% | 12.45B |
- Stock Market
- Equities
- NRBO Stock
- News NeuroBo Pharmaceuticals, Inc.
- NeuroBo Pharmaceuticals Names Marshall Woodworth Finance Chief